<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005848</url>
  </required_header>
  <id_info>
    <org_study_id>Kamada-AAT(IV)-011</org_study_id>
    <nct_id>NCT02005848</nct_id>
  </id_info>
  <brief_title>Phase II-III Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes</brief_title>
  <official_title>Phase II-III Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kamada, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kamada, Ltd.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pivotal, Phase II-III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study
      Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the
      Treatment of New Onset Type-1 Diabetes.

      A sample size of 192 patients is planned, with 64 patients randomized to each of the three
      study groups.

      The study objectives are:

        -  To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes

        -  To assess the safety  and tolerability of intravenous AAT in new onset Type 1 Diabetes
           pediatric and young adult population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Beta cell function</measure>
    <time_frame>12 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Beta cell function (measured by C peptide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>24 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycemic control expressed in HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta cell function</measure>
    <time_frame>24 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>24 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>24 months from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>24 months from baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, vital signs, physical examination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>New Onset Type-1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Alpha1 Antitrypsin (Glassia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha-1 Antitrypsin (Glassia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alpha-1 Antitrypsin</intervention_name>
    <arm_group_label>Alpha1 Antitrypsin (Glassia)</arm_group_label>
    <arm_group_label>Alpha-1 Antitrypsin (Glassia)</arm_group_label>
    <other_name>Humman Alpha-1 Antitrypsin</other_name>
    <other_name>Alpha-1 Proteinase Inhibitor</other_name>
    <other_name>API</other_name>
    <other_name>AAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Subject (or parent/guardian) willing and able to sign an informed consent

          -  Age 8-25 (inclusive) years

          -  Recently diagnosed with T1DM

          -  Basal C-peptide ≥ 0.2 pmol/mL

          -  Positive for at least one diabetes-related autoantibody

          -  Ability and consent to comply with completion of patient diary

          -  No significant abnormalities in serum hematology, serum chemistry

          -  No significant abnormalities in urinalysis

          -  No significant abnormalities in ECG

          -  For women of child bearing potential,  non-pregnant, non-lactating female patients

        Main Exclusion Criteria:

          -  IgA deficient subjects

          -  Subjects who have received an active/ live virus vaccine within 4 weeks of the
             screening date

          -  Subjects who have received treatment with corticosteroid medication within 2 months
             prior to screening or any immunosuppressant or cytostatic agent within 6 months prior
             to screening

          -  Individuals with a history of severe immediate hypersensitivity reactions, including
             anaphylaxis, to plasma products

          -  Clinically significant intercurrent illnesses

          -  Pregnant or lactating women

          -  Current use of any medication known to influence glucose tolerance

          -  Current or prior (within the last 60 days prior to screening visit) use of metformin,
             sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV
             inhibitors or amylin.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Hershkovitz, MD</last_name>
      <email>elih@bgu.ac.il</email>
    </contact>
    <investigator>
      <last_name>Eli Hershkovitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naim Shehadeh, Prof.</last_name>
      <email>n_shehadeh@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Naim Shehadeh, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Pethach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael Lebenthal, MD</last_name>
      <email>Yaell@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yael Lebenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Rachmiel, MD</last_name>
      <email>rmarianna@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marianna Rachmiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type-1 Diabetes</keyword>
  <keyword>T1D</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
